| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Consun Pharmaceutical Group Limited Reveals Advance In Full Year Profit | 1 | RTTNews | ||
| Do | Consun Pharmaceutical Full-Year Net Profit RMB1.078 Billion, Up 18.4%; Final Dividend HKD0.4 | 2 | AASTOCKS | ||
| Do | CONSUN PHARMA (01681): FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025 | 5 | HKEx | ||
| Do | CONSUN PHARMA (01681): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025 | 2 | HKEx | ||
| 05.03. | CONSUN PHARMA (01681): NOTICE OF BOARD MEETING | 8 | HKEx | ||
| 13.02. | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 29.01. | CONSUN PHARMA (01681): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE PROGRAM UNDER THE REPURCHASE MANDATE | - | HKEx | ||
| 19.01. | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| CONSUN PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 06.01. | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 23.12.25 | CONSUN PHARMA (01681): TERMS OF REFERENCE OF THE ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 23.12.25 | CONSUN PHARMA (01681): THIRD AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 23.12.25 | CONSUN PHARMA (01681): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 23 DECEMBER 2025 | 3 | HKEx | ||
| 10.12.25 | CONSUN PHARMA (01681): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): 2025 SHARE AWARD SCHEME | 1 | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): NOTIFICATION LETTER TO SHAREHOLDERS - EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 3 | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 08.12.25 | CONSUN PHARMA (01681): (1) PROPOSED ADOPTION OF THE SHARE AWARD SCHEME, (2) PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION ... | 1 | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 106,90 | 0,00 % | EQS-DD: Merck KGaA: Belén Garijo Lopez, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
25.03.2026 / 10:59... ► Artikel lesen | |
| GILEAD SCIENCES | 118,32 | -0,22 % | Gilead mit Doppelschlag | Zwei milliardenschwere Übernahmen in einem Monat: Die Biotech-Gesellschaft Gilead bleibt äußerst aktiv in Sachen M&A. Nachdem die Amerikaner bereits am 23. Februar die Akquisition des Partners Arcellx... ► Artikel lesen | |
| TEVA | 25,700 | -0,39 % | Jefferies reiterates Teva stock rating on pipeline potential | ||
| DERMAPHARM | 44,500 | 0,00 % | EQS-AFR: Dermapharm Holding SE: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Dermapharm Holding SE
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Dermapharm Holding SE: Vorabbekanntmachung... ► Artikel lesen | |
| SINOPHARM | 2,234 | -0,13 % | Reed Sinopharm Exhibitions (RSE): PCHi 2026: World's Largest Cosmetics Ingredients Exhibition Opens in Hangzhou | 860+ exhibitors from 26 countries and regions across 70,000 sqmClose to 50 new product launches, including global and China debuts295 product submissions and 19 engineer nominations for the... ► Artikel lesen | |
| CSPC PHARMA | 1,007 | +13,99 % | HSI Adds 135 Pts at Midday as BYD COMPANY Leaps 4%+; CSPC PHARMA Surges 10% | ||
| WUXI BIOLOGICS | 3,480 | -0,23 % | WuXi Biologics Reports Record 2025 Annual Results | Revenue increased 16.7% YoY to RMB 21.8 billion, and revenue from continuous operations grew over 20% YoY
IFRS gross profit margin expanded to 46.0% (+500 bps... ► Artikel lesen | |
| OPKO HEALTH | 0,960 | -5,04 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| COSMO PHARMACEUTICALS | 89,00 | +0,56 % | Cosmo Pharmaceuticals N.V.: Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026 | Dublin, Ireland--(Newsfile Corp. - March 16, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) ("Cosmo") today announced its participation at NVIDIA GTC 2026, the world's leading conference... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 2,022 | -1,17 % | Fosun Pharma Announces 2025 Annual Results | Innovation and Globalization Propel Fosun Pharma's High-Quality Growth
SHANGHAI, March 24, 2026 /PRNewswire/ -- On 24 March, 2026, Fosun Pharma ("the company",... ► Artikel lesen | |
| GEDEON RICHTER | 30,200 | -1,24 % | Gedeon Richter Plc.: Extraordinary Information | ||
| DR REDDYS | 11,800 | 0,00 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| BAYER | 38,275 | 0,00 % | DAX-Check LIVE: Aroundtown, Bayer, Beiersdorf, Elmos, Fuchs, Infineon, Lanxess im Fokus | Die Eskalation im Nahost-Krieg hat die Märkte erneut stark belastet. Steigende Energiepreise und wachsende Konjunktursorgen sorgten für eine deutliche Flucht aus Aktien. Der DAX sackte im Tagesverlauf... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 73,46 | 0,00 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| GSK | 23,660 | 0,00 % | FDA genehmigt Lynavoy von GSK zur Behandlung von Juckreiz bei PBC | Der britische Pharmakonzern GSK plc hat die Zulassung seines Medikaments Lynavoy in den USA erhalten. Die US-Arzneimittelbehörde U.S. Food and Drug Administration genehmigte das Präparat zur Behandlung... ► Artikel lesen |